Avalyn Pharma Inc. filed an 8-K on September 16, 2026, disclosing that its Board of Directors appointed Robert Meyer, M.D. as a Class II director, effective September 15, 2026.

Key Highlights

  • New director appointed: Robert Meyer, M.D. joined the Avalyn Pharma Board as a Class II director with an initial term expiring at the 2028 annual meeting of stockholders.
  • Independence confirmed: The Board determined that Dr. Meyer is independent under Nasdaq listing standards.
  • Initial equity grant: Dr. Meyer received an option to purchase 31,182 shares of common stock, vesting in equal annual installments over three years from the date of grant.
  • Annual cash retainer: Dr. Meyer is eligible to receive an annual retainer of $40,000 under the Company's Non-Employee Director Compensation Policy.
  • Annual option grant: Dr. Meyer will be eligible to receive annual stock option grants to purchase 15,591 shares of common stock following each annual stockholder meeting.
  • Regulatory background: Dr. Meyer worked at the FDA from 1994 to 2007, including as Director of the Office of Drug Evaluation II in the Center for Drug Evaluation and Research from 2002 to 2007.

Dr. Meyer's Background and Compensation at Avalyn Pharma

According to the filing, Dr. Meyer brings extensive regulatory and life sciences experience to the Avalyn Pharma board. He served at the FDA from 1994 to 2007, holding roles including Director of the Division of Pulmonary and Allergy Drug Products from 1999 to 2002, and Director of the Office of Drug Evaluation II from 2002 to 2007. He subsequently joined Merck & Co., Inc. in October 2007, serving as Vice President and Head of Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories from November 2009 until January 2013.

The filing further disclosed that from January 2018 to October 2024, Dr. Meyer was a principal of the Drug and Biologic Products team at Greenleaf Health Inc., an FDA strategic consulting company later acquired by Eliquent Life Sciences. He also held an associate professor role at the University of Virginia School of Medicine from March 2013 to December 2017. His prior public company board service, as disclosed in the filing, includes Chimerix, Inc. from 2018 to 2025, Translate Bio from 2019 to 2021, and Correvio Pharma Corp. from 2015 to 2020.

Under the Company's Non-Employee Director Compensation Policy, the initial option grant of 31,182 shares will vest in equal annual installments over three years. Future annual grants of 15,591 shares will vest upon the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders. The filing noted that each option has a per share exercise price equal to the Fair Market Value of the common stock on the date of grant, as defined in the Company's 2026 Stock Option and Incentive Plan. The filing also stated that there are no arrangements or understandings between Dr. Meyer and any other person pursuant to which he was selected as a director, and that he is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.

What Was Disclosed

Avalyn Pharma Inc. (NASDAQ:AVLN) disclosed the appointment of Robert Meyer, M.D. as a Class II independent director, effective September 15, 2026, along with the compensation terms governing his service under the Company's Non-Employee Director Compensation Policy.